Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Orthostatic hypotension and postural tachycardia (POTS)

Cardiovascular · Symptom or situation · updated 2026-10-30

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Orthostatic hypotension: 5% of middle-aged adults, about 20% after age 60 [1]

Confirmed orthostatic hypotension

In the practice

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Suspected postural tachycardia (POTS)

In the practice

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

On midodrine or fludrocortisone: monitoring

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (15)
  1. Kim MJ, Farrell J. Orthostatic hypotension: a practical approach. Am Fam Physician. 2022;105(1):39-49.
  2. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567-1582.
  3. Pathak A, Elghozi JL, Fortrat JO, Senard JM, Hanon O. Prise en charge de l’hypotension orthostatique. Consensus d’experts de la Société française d’hypertension artérielle (SFHTA), de la Société française de gériatrie et gérontologie (SFGG) et de l’European Federation of Autonomic Societies (EFAS). Décembre 2014.
  4. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-1948.
  5. National Institute for Health and Care Excellence (NICE). Transient loss of consciousness ('blackouts') in over 16s. Clinical guideline CG109, août 2010, mise à jour 21 novembre 2023.
  6. National Institute for Health and Care Excellence (NICE). Falls: assessment and prevention in older people and in people 50 and over at higher risk. Guideline NG249, 29 avril 2025.
  7. Montero-Odasso M, van der Velde N, Martin FC, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51(9):afac205.
  8. Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41-63.
  9. Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton Neurosci. 2021;235:102828.
  10. Résumé des caractéristiques du produit GUTRON 2,5 mg, comprimé (midodrine). Base de données publique des médicaments, RCP mis à jour le 17/05/2021.
  11. Summary of product characteristics. Bramox 2.5 mg tablets (midodrine). electronic medicines compendium (Royaume-Uni), texte révisé le 19/04/2022.
  12. Zorginstituut Nederland. Farmacotherapeutisch Kompas : midodrine (Pays-Bas), consulté le 30 octobre 2026.
  13. Federatie Medisch Specialisten (Pays-Bas). Preventie van valincidenten bij ouderen : module « Medicamenteuze behandeling van orthostatische hypotensie » (2023 ; publié sur le site le 19/02/2026, validité évaluée le 06/02/2024). Richtlijnendatabase.
  14. National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults. Guideline NG71, 19 juillet 2017.
  15. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope. J Am Coll Cardiol. 2017;70(5):e39-e110.